Proteomics International Laboratories Ltd (PIQ.AX) September 2024 Quarterly Activities Report

Proteomics International Laboratories Ltd (ASX:PIQ), a pioneer in predictive diagnostics and precision medicine is pleased to provide the following update on its business activities for the three months to 30 September 2024 and subsequent to the period end.

The quarterly report updates are listed below:

- World first blood test for esophageal cancer shows 94% accuracy: results demonstrated outstanding diagnostic performance for identifying patients with esophageal adenocarcinoma (EAC) in a clinical validation study.

- Groundbreaking study on PromarkerD and type 1 diabetes and kidney health: results show PromarkerD demonstrated high accuracy in predicting chronic kidney disease in this new group of patients (all previous applications were directed at patients with type 2 diabetes).

- Update on commercialisation of PromarkerD: Proteomics International is targeting a US launch in H1 CY25, and an Australian launch in Q1 CY25 through a hybrid approach of traditional licensing and direct-to-consumer/patient (DTC/DTP) Go-to-Market strategies.

- PromarkerEndo and PromarkerEso tests advance

- Analytical Services: ISO 17025 certification successfully renewed following audit by National Association of Testing Authorities (NATA).

- Events and Marketing

- Financial and Corporate Highlights: Appointment of Dr James Williams as an independent nonexecutive director and deputy chair.

- Target share price catalysts FY25

*To view the Quarterly Report, please visit:
https://abnnewswire.net/lnk/MHO212E5

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel 
Investor Relations & Corporate Advisor
Candour Advisory
T: +61 408 326 367 
E: dirk@candouradvisory.com.au

Andrew Williams
Public Relations
Profile Media
T: +61 412 614 125
E: andreww@profilemedia.com.au

News Provided by ABN Newswire